Novel therapeutic interventions for combating Parkinson’s disease and prospects of Nose-to-Brain drug delivery
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel therapeutic interventions for combating Parkinson’s disease and prospects of Nose-to-Brain drug delivery
Authors
Keywords
Parkinson's disease, Dopamine, Stem cell therapy, Nucleic acid therapy, Nanomedicine, Nose-to-brain delivery, Viral vector-mediated delivery
Journal
BIOCHEMICAL PHARMACOLOGY
Volume 195, Issue -, Pages 114849
Publisher
Elsevier BV
Online
2021-11-20
DOI
10.1016/j.bcp.2021.114849
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat
- (2021) Cynthia Kwan et al. BEHAVIOURAL PHARMACOLOGY
- Opicapone: A Review in Parkinson’s Disease
- (2021) Lesley J. Scott CNS DRUGS
- Safety and efficacy of tolcapone in Parkinson’s disease: systematic review
- (2021) Carlo Alberto Artusi et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Neuroprotective potential of cinnamon and its metabolites in Parkinson's disease: Mechanistic insights, limitations, and novel therapeutic opportunities
- (2021) Efthalia Angelopoulou et al. JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
- Cyto/Biocompatibility of Dopamine Combined with the Antioxidant Grape Seed-Derived Polyphenol Compounds in Solid Lipid Nanoparticles
- (2021) Adriana Trapani et al. MOLECULES
- Bioinspired Theranostic Coordination Polymer Nanoparticles for Intranasal Dopamine Replacement in Parkinson’s Disease
- (2021) Javier García-Pardo et al. ACS Nano
- Neuroinflammatory Mechanisms of Mitochondrial Dysfunction and Neurodegeneration in Glaucoma
- (2021) Joao N. Duarte Journal of Ophthalmology
- Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside
- (2021) Awanish Mishra et al. METABOLIC BRAIN DISEASE
- Parkinson’s Kinetigraph in the Selection of Levodopa-Carbidopa Intestinal Gel for Motor Fluctuations Refractory to Deep Brain Stimulation
- (2021) Yassine Noui et al. Journal of Movement Disorders
- Nanotechnology-based drug delivery for central nervous system disorders
- (2021) Thuy Trang Nguyen et al. BIOMEDICINE & PHARMACOTHERAPY
- Potential applications of nanomedicine for treating Parkinson's disease
- (2021) Jyotsna Shankar et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- iPSC modeling of young-onset Parkinson’s disease reveals a molecular signature of disease and novel therapeutic candidates
- (2020) A. H. Laperle et al. NATURE MEDICINE
- The future of stem cell therapies for Parkinson disease
- (2020) Malin Parmar et al. NATURE REVIEWS NEUROSCIENCE
- In Vitro and in Vivo Evaluation of Levodopa Loaded Nanoparticles for Nose to Brain Delivery
- (2020) Sema Arisoy et al. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
- Nose-to-Brain Delivery
- (2020) Paolo Giunchedi et al. Pharmaceutics
- The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
- (2020) Miren Ettcheto et al. Expert Opinion on Drug Discovery
- Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease
- (2020) Subrat K. Bhattamisra et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Nasal administration of nanoencapsulated geraniol/ursodeoxycholic acid conjugate: Towards a new approach for the management of Parkinson's disease
- (2020) Edilson Ribeiro de Oliveira Junior et al. JOURNAL OF CONTROLLED RELEASE
- Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders
- (2020) Salman Ul Islam et al. MOLECULES
- Nanostructured Lipid Carriers (Nlcs): Nose-to-Brain Delivery and Theranostic Application
- (2020) Javed Ahmad et al. CURRENT DRUG METABOLISM
- Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson’s disease management
- (2020) Piyong Sola et al. Expert Opinion on Drug Delivery
- Parkinson’s disease: etiopathogenesis and treatment
- (2020) Joseph Jankovic et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis
- (2020) Clive G. Ballard et al. PARKINSONISM & RELATED DISORDERS
- Current and projected future economic burden of Parkinson’s disease in the U.S.
- (2020) Wenya Yang et al. npj Parkinsons Disease
- Ongentys (Opicapone): A New COMT Inhibitor for the Treatment of Parkinson’s Disease
- (2020) Erin St. Onge et al. ANNALS OF PHARMACOTHERAPY
- Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa‐carbidopa intrajejunal gel
- (2020) Marta Melis et al. EUROPEAN JOURNAL OF NEUROLOGY
- Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson's disease
- (2020) Jian-Nan Zhang et al. MOLECULAR AND CELLULAR NEUROSCIENCE
- Engineering precision nanoparticles for drug delivery
- (2020) Michael J. Mitchell et al. NATURE REVIEWS DRUG DISCOVERY
- Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset
- (2020) Cynthia Kwan et al. NEUROPHARMACOLOGY
- Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia
- (2019) Rhyomi C. Sellnow et al. Acta Neuropathologica Communications
- Fabrication, Optimization, and Evaluation of Rotigotine-Loaded Chitosan Nanoparticles for Nose-To-Brain Delivery
- (2019) Angeline Tzeyung et al. Pharmaceutics
- Nucleic Acid–Based Therapeutics for Parkinson’s Disease
- (2019) Masayuki Nakamori et al. Neurotherapeutics
- Rational approaches for toxicological assessments of nanobiomaterials
- (2019) Shalabh Pandey et al. JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
- Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease
- (2019) Roger A. Barker et al. NATURE MEDICINE
- The kainate receptor antagonist UBP310 but not single deletion of GluK1, GluK2, or GluK3 subunits, inhibits MPTP-induced degeneration in the mouse midbrain
- (2019) Sandy Stayte et al. EXPERIMENTAL NEUROLOGY
- Intranasal drug delivery: Novel delivery route for effective management of neurological disorders
- (2019) Ashwini Patel et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- Safety Profile of Opicapone in the Management of Parkinson’s Disease
- (2019) Andrew Lees et al. Journal of Parkinsons Disease
- Mesenchymal Stem Cells for Regenerative Medicine
- (2019) Yu Han et al. Cells
- Parkinson disease
- (2019) R. Balestrino et al. EUROPEAN JOURNAL OF NEUROLOGY
- Serotonin 5-HT4 Receptor Agonists Improve Facilitation of Contextual Fear Extinction in An MPTP-Induced Mouse Model of Parkinson’s Disease
- (2019) Ishii et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Neuroprotective and Antioxidant Effect of Naringenin-Loaded Nanoparticles for Nose-to-Brain Delivery
- (2019) Shadab Md et al. Brain Sciences
- Evolving nanoformulation strategies for diagnosis and clinical interventions for Parkinson’s disease
- (2019) Sunita Chawla et al. DRUG DISCOVERY TODAY
- Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease by metabolomic technology
- (2018) Yong Wang et al. BEHAVIOURAL BRAIN RESEARCH
- Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity
- (2018) Ruhi Raj et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia
- (2018) Annalisa Pinna et al. JOURNAL OF NEURAL TRANSMISSION
- Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia
- (2018) Santiago Perez-Lloret et al. JOURNAL OF NEURAL TRANSMISSION
- The highly selective 5-HT 2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l -DOPA-treated parkinsonian marmoset
- (2018) Adjia Hamadjida et al. NEUROPHARMACOLOGY
- Theranostic applications of nanoparticles in neurodegenerative disorders
- (2018) Sahana Ramanathan et al. International Journal of Nanomedicine
- Dextran-coated iron oxide nanoparticle-improved therapeutic effects of human mesenchymal stem cells in a mouse model of Parkinson's disease
- (2018) Tsai-Hua Chung et al. Nanoscale
- Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts
- (2018) Alberto J. Espay et al. ANNALS OF NEUROLOGY
- Safety and effectiveness of istradefylline in patients with Parkinson’s disease: interim analysis of a post-marketing surveillance study in Japan
- (2018) Makio Takahashi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Magnetic Resveratrol Liposomes as a New Theranostic Platform for Magnetic Resonance Imaging Guided Parkinson’s Disease Targeting Therapy
- (2018) Meili Wang et al. ACS Sustainable Chemistry & Engineering
- Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study
- (2017) Emanuele Cereda et al. JOURNAL OF NEUROLOGY
- Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone
- (2017) JinW Cho et al. NEUROLOGY INDIA
- Expanding the repertoire of L-DOPA’s actions: A comprehensive review of its functional neurochemistry
- (2017) Philippe De Deurwaerdère et al. PROGRESS IN NEUROBIOLOGY
- The catechol- O -methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells
- (2017) David Grünig et al. TOXICOLOGY IN VITRO
- The effect of istradefylline for Parkinson’s disease: A meta-analysis
- (2017) Wataru Sako et al. Scientific Reports
- Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations
- (2017) Anthony H. V. Schapira et al. JAMA Neurology
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)
- (2017) Rajesh Pahwa et al. JAMA Neurology
- Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson’s Disease
- (2017) Christin Helmschrodt et al. Molecular Therapy-Nucleic Acids
- Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment
- (2016) Chenchen Bi et al. International Journal of Nanomedicine
- Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms
- (2016) Veronica Ghiglieri et al. NEUROBIOLOGY OF DISEASE
- Chronic 5-HT3 receptor antagonism ameliorates seizures and associated memory deficit in pentylenetetrazole-kindled mice
- (2016) Awanish Mishra et al. NEUROSCIENCE
- Antisense oligonucleotides in therapy for neurodegenerative disorders
- (2015) Melvin M. Evers et al. ADVANCED DRUG DELIVERY REVIEWS
- Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
- (2015) Per Svenningsson et al. BRAIN
- A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease
- (2015) Tomoyoshi Kondo et al. CLINICAL NEUROPHARMACOLOGY
- shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson’s disease model
- (2015) Alevtina D. Zharikov et al. JOURNAL OF CLINICAL INVESTIGATION
- Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review
- (2015) Abhijeet D. Kulkarni et al. JOURNAL OF DRUG TARGETING
- Activity of serotonin 5-HT1A receptor ‘biased agonists’ in rat models of Parkinson's disease and l-DOPA-induced dyskinesia
- (2015) H. Iderberg et al. NEUROPHARMACOLOGY
- The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque
- (2015) Philippe Huot et al. NEUROPHARMACOLOGY
- Activation and blockade of serotonin7 receptors in the prelimbic cortex regulate depressive-like behaviors in a 6-hydroxydopamine-induced Parkinson’s disease rat model
- (2015) Q.J. Zhang et al. NEUROSCIENCE
- Amido-bridged nucleic acids with small hydrophobic residues enhance hepatic tropism of antisense oligonucleotides in vivo
- (2015) Tsuyoshi Yamamoto et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- L -DOPA-Coated Manganese Oxide Nanoparticles as Dual MRI Contrast Agents and Drug-Delivery Vehicles
- (2015) Birgitte Hjelmeland McDonagh et al. Small
- Foetal Cell Transplantation for Parkinson’s Disease: Focus on Graft-Induced Dyskinesia
- (2015) Elisabetta Tronci et al. Parkinsons Disease
- Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: Positive and negative effects
- (2014) Christina E. Khodr et al. BRAIN RESEARCH
- Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method
- (2014) Shadab Md et al. Expert Opinion on Drug Delivery
- Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients
- (2014) Marios Politis et al. JOURNAL OF CLINICAL INVESTIGATION
- Potential for cell therapy in Parkinson's disease using genetically programmed human embryonic stem cell-derived neural progenitor cells
- (2014) Rajesh Ambasudhan et al. JOURNAL OF COMPARATIVE NEUROLOGY
- Clinical spectrum of levodopa-induced complications
- (2014) Camila Catherine Aquino et al. MOVEMENT DISORDERS
- Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice
- (2014) J. Mark Cooper et al. MOVEMENT DISORDERS
- The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson’s disease: a randomized, double-blind, double-dummy, parallel-group study
- (2014) Ying Wang et al. Translational Neurodegeneration
- Theranostic Nanomedicine with Functional Nanoarchitecture
- (2013) Dipanjan Pan MOLECULAR PHARMACEUTICS
- Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
- (2013) Rupam Borgohain et al. MOVEMENT DISORDERS
- Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex
- (2013) Takako Kadowaki Horita et al. PSYCHOPHARMACOLOGY
- Pre-conditioned mesenchymal stem cells: a better way for cell-based therapy
- (2013) Qing Li et al. Stem Cell Research & Therapy
- Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease
- (2013) Zinovia Kefalopoulou et al. JAMA Neurology
- Probing of the Assembly Structure and Dynamics within Nanoparticles during Interaction with Blood Proteins
- (2012) Yuanpei Li et al. ACS Nano
- Multicolored pH-Tunable and Activatable Fluorescence Nanoplatform Responsive to Physiologic pH Stimuli
- (2012) Kejin Zhou et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease
- (2012) Roger A Barker et al. LANCET NEUROLOGY
- Targeting nuclear RNA for in vivo correction of myotonic dystrophy
- (2012) Thurman M. Wheeler et al. NATURE
- Generation of Regionally Specified Neural Progenitors and Functional Neurons from Human Embryonic Stem Cells under Defined Conditions
- (2012) Agnete Kirkeby et al. Cell Reports
- Theranostic Nanomedicine
- (2011) Xiaoyuan Chen et al. ACCOUNTS OF CHEMICAL RESEARCH
- Multifunctional nanoparticles for multimodal imaging and theragnosis
- (2011) Dong-Eun Lee et al. CHEMICAL SOCIETY REVIEWS
- Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration
- (2011) Ziyi Wen et al. JOURNAL OF CONTROLLED RELEASE
- AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
- (2011) Peter A LeWitt et al. LANCET NEUROLOGY
- Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease
- (2011) Sonja Kriks et al. NATURE
- Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa
- (2011) Yoland Smith et al. NEUROPSYCHOPHARMACOLOGY
- Nanoparticle-based theranostic agents
- (2010) Jin Xie et al. ADVANCED DRUG DELIVERY REVIEWS
- Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
- (2010) Paolo Calabresi et al. LANCET NEUROLOGY
- Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
- (2010) William J Marks et al. LANCET NEUROLOGY
- In Vivo RNAi-Mediated α-Synuclein Silencing Induces Nigrostriatal Degeneration
- (2010) Oleg S Gorbatyuk et al. MOLECULAR THERAPY
- α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra
- (2010) Alison L. McCormack et al. PLoS One
- Computationally Guided Photothermal Tumor Therapy Using Long-Circulating Gold Nanorod Antennas
- (2009) G. von Maltzahn et al. CANCER RESEARCH
- mGluR4-positive allosteric modulation as potential treatment for Parkinson’s disease
- (2009) Corey R Hopkins et al. Future Medicinal Chemistry
- Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys
- (2009) Laurent Grégoire et al. PARKINSONISM & RELATED DISORDERS
- [11C]-PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?
- (2009) A.L. Bartels et al. PARKINSONISM & RELATED DISORDERS
- Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats
- (2009) Amit Gupta et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, Physicochemical Characterizations, and Biological Applications
- (2008) Sophie Laurent et al. CHEMICAL REVIEWS
- Newly Synthesized Water Soluble Cholinium-Purpurin Photosensitizers and Their Stabilized Gold Nanoparticles as Promising Anticancer Agents
- (2008) Dorjnamjin Demberelnyamba et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- In vivo silencing of alpha-synuclein using naked siRNA
- (2008) Jada Lewis et al. Molecular Neurodegeneration
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation